BDTX

1.3353.96%
MA

Mark A. Velleca

CEO, President & Chairman

Dr. Mark A. Velleca, M.D., Ph. D., is Director of Myeloid Therapeutics, Inc and served as its Chairman of the Board. He serves as President & Chief Executive Officer at Black Diamond Therapeutics, Inc. since September 16, 2023 and serves as its Chairman since December 2022. He has been an Independent Director of Black Diamond Therapeutics, Inc. since August 2021. He served as President at StrideBio, Inc. since 2022 and has been its Chief Executive Officer & Director since February 2022. He is Director at Black Diamond Therapeutics, Inc. since August 2021 and is its Chairman since December 2022. He serves as Chair of the Board of Turbine Hálózatelemzo Kutatási Fejlesztési Kft since April 2021. He has been Advisor of G1 Therapeutics, Inc. since January 1, 2021. Dr. Velleca served as Chief Executive Officer of G1 Therapeutics, Inc. since May 20, 2014 until December 2020 and had been its President since May 2014 until December 2020 and served as its Director since May 2014 until September 30, 2023. Dr. Velleca served as Senior Advisor at Gilead Sciences, Inc. from 2010 to April 2012, where he worked to help build its oncology pipeline. He serves as Venture Partner at Hatteras Venture Partners and also serves as Chair of the Board of Directors at Turbine Simulated Cell Technologies Ltd and served as its Director at IMMvention Therapeutix, Inc. Dr. Velleca also served as an attending physician at Yale New Haven Hospital and on the faculty of the Yale University School of Medicine. He was a Co-Founder of CGI Pharmaceuticals, Inc. and served as its Senior Vice President from 1999 to 2010. He served as Executive Vice President at The Leukemia & Lymphoma Society (LLS) from April 2012 to April 2014. Dr. Velleca joined LLS in 2012 as Chief policy and advocacy officer and was responsible for the strategy and implementation of its legislative and regulatory policy initiatives. He served as Vice President of Research and Preclinical Development of CGI Pharmaceuticals, Inc. Dr. Velleca serves as First Employee at CGI and one of its founding scientists. He has broad-based experience in both basic biomedical research and clinical medicine. He is expertise in the laboratory diagnosis of autoimmune/inflammatory diseases, hematological disorders and cancer, as well as the treatment of cancer patients via stem cell transplantation. He served as Chief Scientific Officer of CGI Pharmaceuticals, Inc. Since CGI's formation, Dr. Velleca has played a leading role in the design and implementation of its scientific strategy for drug discovery and development. He was Chief Resident at Yale New Haven Hospital. He served as a Member of Scientific Advisory Board at BioRelix, Inc from 2007 to 2012. He served as a Director of BioMarker Strategies, LLC from 2010 to 2012. He served as a Member of Scientific Advisory Board of Intellikine, Inc. from 2007 to 2010. Dr. Velleca was on the faculty of Yale Medical School. He has published papers in diverse areas of cell and molecular biology, signal transduction, immunology, neuroscience and transfusion medicine. He is the recipient of a NIH Physician/ Scientist Career Award. He is a Board-Certified Clinical Pathologist. Dr. Velleca earned his B. S. Cum Laude from Yale University and is a graduate of the Medical Scientist Training Program at Washington University. He received an M. D. and a Ph. D. in the Neurosciences from Washington University in St. Louis. After completing clinical training at Yale New Haven Hospital, Dr. Velleca did postdoctoral research in Cell Biology and Immunobiology at Yale Medical School.

Positions